InvestorsHub Logo

MWM

Followers 1062
Posts 141582
Boards Moderated 14
Alias Born 03/31/2006

MWM

Re: None

Monday, 03/29/2021 1:12:47 PM

Monday, March 29, 2021 1:12:47 PM

Post# of 42674
In the treatment group, the Kaplan-Meier estimate for invasive mechanical ventilation and/or death was 15.6%, compared to 22.1% in the placebo group. Humanigen also reported a “favorable trend” in the mortality rate, which was 9.6% in the lenzilumab arm and 13.9% in the placebo group. Analysts at Cantor said the "homerun" data "could translate to blockbuster sales in COVID-19 this year."
$HGEN

https://www.fiercebiotech.com/biotech/humanigen-s-covid-19-phase-3-hits-goal-sending-stock-soaring